Robert B. Garland

1.2k total citations
26 papers, 925 citations indexed

About

Robert B. Garland is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Robert B. Garland has authored 26 papers receiving a total of 925 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Organic Chemistry and 8 papers in Oncology. Recurrent topics in Robert B. Garland's work include Peptidase Inhibition and Analysis (6 papers), Platelet Disorders and Treatments (4 papers) and Protein Degradation and Inhibitors (4 papers). Robert B. Garland is often cited by papers focused on Peptidase Inhibition and Analysis (6 papers), Platelet Disorders and Treatments (4 papers) and Protein Degradation and Inhibitors (4 papers). Robert B. Garland collaborates with scholars based in United States and United Kingdom. Robert B. Garland's co-authors include Steven K. Davidsen, Michael L. Curtin, Patrick A. Marcotte, Michael Harré, A. I. MEYERS, Robin R. Frey, Lori J. Pease, Keith B. Glaser, Michael R. Michaelides and Junling Li and has published in prestigious journals such as Journal of the American Chemical Society, Biochemical and Biophysical Research Communications and Journal of Medicinal Chemistry.

In The Last Decade

Robert B. Garland

25 papers receiving 867 citations

Peers

Robert B. Garland
Chu‐Biao Xue United States
Jack A. Kauffman United States
Rainer Metternich Switzerland
Robert A. Galemmo United States
Michael N. Greco United States
Lawrence A. Reiter United States
Steve Tam United States
Adel M. Naylor-Olsen United States
Thomas W. Ku United States
Zaihui Zhang Canada
Chu‐Biao Xue United States
Robert B. Garland
Citations per year, relative to Robert B. Garland Robert B. Garland (= 1×) peers Chu‐Biao Xue

Countries citing papers authored by Robert B. Garland

Since Specialization
Citations

This map shows the geographic impact of Robert B. Garland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert B. Garland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert B. Garland more than expected).

Fields of papers citing papers by Robert B. Garland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert B. Garland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert B. Garland. The network helps show where Robert B. Garland may publish in the future.

Co-authorship network of co-authors of Robert B. Garland

This figure shows the co-authorship network connecting the top 25 collaborators of Robert B. Garland. A scholar is included among the top collaborators of Robert B. Garland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert B. Garland. Robert B. Garland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cohan, Stanley, Kyle Smoot, Robert B. Garland, et al.. (2018). Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study. Advances in Therapy. 35(11). 1894–1904. 5 indexed citations
2.
Glaser, Keith B., Lori J. Pease, Michael J. Staver, et al.. (2004). Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochemical and Biophysical Research Communications. 325(3). 683–690. 51 indexed citations
3.
Wada, Carol K., Robin R. Frey, Zhiqin Ji, et al.. (2003). α-Keto amides as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 13(19). 3331–3335. 67 indexed citations
4.
Curtin, Michael L., Robert B. Garland, H. Robin Heyman, et al.. (2002). Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorganic & Medicinal Chemistry Letters. 12(20). 2919–2923. 97 indexed citations
5.
Frey, Robin R., Carol K. Wada, Robert B. Garland, et al.. (2002). Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorganic & Medicinal Chemistry Letters. 12(23). 3443–3447. 116 indexed citations
6.
Wada, Carol K., James H. Holms, Michael L. Curtin, et al.. (2001). Phenoxyphenyl SulfoneN-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors. Journal of Medicinal Chemistry. 45(1). 219–232. 81 indexed citations
7.
Marcotte, Patrick A., Zhiwen Guan, Terrance J. Magoc, et al.. (1999). Evaluation of the Inhibition of other Metalloproteinases by Matrix Metalloproteinase Inhibitors. Journal of enzyme inhibition. 14(6). 425–435. 6 indexed citations
8.
Ernst, Armin, Robert B. Garland, & John F. Beamis. (1999). Photodynamic Therapy in Lung Cancer. Journal of Bronchology. 6(4). 285–288. 9 indexed citations
9.
Steinman, Douglas H., Michael L. Curtin, Robert B. Garland, et al.. (1998). The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(16). 2087–2092. 26 indexed citations
10.
Curtin, Michael L., Robert B. Garland, Steven K. Davidsen, et al.. (1998). Broad spectrum matrix metalloproteinase inhibitors: An examination of succinamide hydroxamate inhibitors with P1 Cα gem-disubstitution. Bioorganic & Medicinal Chemistry Letters. 8(12). 1443–1448. 8 indexed citations
11.
Zablocki, Jeffery A., Foe S. Tjoeng, Philippe R. Bovy, et al.. (1995). A novel series of orally active antiplatelet agents. Bioorganic & Medicinal Chemistry. 3(5). 539–551. 30 indexed citations
12.
Rico, Joseph G., Robert B. Garland, Thomas E. Rogers, et al.. (1995). Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists. Journal of Medicinal Chemistry. 38(13). 2378–2394. 86 indexed citations
13.
Bovy, Philippe R., F. S. TJOENG, Thomas E. Rogers, et al.. (1994). Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents. Bioorganic & Medicinal Chemistry. 2(9). 881–895. 10 indexed citations
14.
15.
MEYERS, A. I., Michael Harré, & Robert B. Garland. (1984). Asymmetric synthesis of quaternary carbon centers. Journal of the American Chemical Society. 106(4). 1146–1148. 78 indexed citations
16.
Garland, Robert B., et al.. (1978). A new synthetic route to 4-demethoxydaunomycinone. Tetrahedron Letters. 19(39). 3669–3672. 16 indexed citations
17.
Pappo, Raphael, et al.. (1973). Asymmetric synthesis of 19-norsteroids. Tetrahedron Letters. 14(21). 1827–1830. 8 indexed citations
18.
19.
Nelson, Norman A. & Robert B. Garland. (1957). Steroidal Hormone Analogs. I. Synthesis of 18,19-Dinorprogesterone and 14-Hydroxy-18,19-dinorprogesterone1. Journal of the American Chemical Society. 79(23). 6313–6320. 8 indexed citations
20.
Taylor, Edward C., et al.. (1956). Pteridines. XIV.1 Further Studies on a New Approach to Pteridine Synthesis2. Journal of the American Chemical Society. 78(1). 210–213. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chu‐Biao Xue Breakdown of academic impact, for papers by Jack A. Kauffman Breakdown of academic impact, for papers by Rainer Metternich Breakdown of academic impact, for papers by Robert A. Galemmo Breakdown of academic impact, for papers by Michael N. Greco Breakdown of academic impact, for papers by Lawrence A. Reiter Breakdown of academic impact, for papers by Steve Tam Breakdown of academic impact, for papers by Adel M. Naylor-Olsen Breakdown of academic impact, for papers by Thomas W. Ku Breakdown of academic impact, for papers by Zaihui Zhang
Rankless by CCL
2026